Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Shein Shares Slide 9% in Hong Kong IPO Debut 
France Targets Shein, Temu With Fast-Fashion Fees 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
Heidelberg, Germany, March 13, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on March 20, 2018, the Company will release its financial results for the quarter and year ended December 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, March 20, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3160515.
United States: +1 786-789-4776
Germany: +49 (0)69 2222 13420
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom:+44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
